Liraglutide (Victoza) ELISA

Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion. It is sold under its trade name Victoza, an injectable drug developed by Novo Nordisk for the treatment of type 2 diabetes. Novo Nordisk also began marketing a separate strength in the U.S. and E.U. under the brand name Saxenda as a treatment for adults who are obese or overweight with at least one weight-related co-morbid condition.

Mechanism of action: Liraglutide is an acylated glucagon-like peptide-1 (GLP-1) agonist, derived from human GLP-1-(7-37), a less common form of endogenous GLP-1. It reduces meal-related hyperglycemia by increasing insulin secretion when required, by increasing glucose levels, delaying gastric emptying, and suppressing post-meal glucagon secretion. Liraglutide leads to insulin release in pancreatic beta cells in the presence of elevated blood glucose. This insulin secretion subsides as glucose concentrations decrease and approach euglycemia (normal blood glucose level). It also decreases glucagon secretion in a glucose-dependent manner and delays gastric emptying. Unlike endogenous GLP-1, liraglutide is stable against metabolic degradation by peptidases.

Principle of the assay: The method employs a sandwich immunoassay for the determination of Liraglutide. The anti-Liraglutide antibodies are coated on microtiter plate. Liraglutide standard and Liraglutide present in the samples will bind to coating antibody. Anti-GLP-1 antibody conjugated to HRP is then added which produces a soluble colored product after addition of TMB substrate. The enzyme reaction is stopped by dispensing of stop solution into the wells. The optical density (OD) of the solution at 450 nm is directly proportional to the amount of bound Liraglutide present in the standards or samples.